The recombination activating gene-1 (RAG-1) and RAG-2 are expressed specifically in immature lymphoid cells undergoing the recombination of antigen receptor genes. The regulation of murine RAG-2 promoter was studied and it was revealed that the ؊41/؊17 RAG-2 promoter region, which is conserved between humans and mice, was indispensable for the RAG-2 promoter activity in B 
Introduction
Immunoglobulin (Ig) and T-cell receptor (TCR) variable genes consist of germline variable (V), diversity (D), and joining (J) segments and are assembled during lymphocyte development by V(D)J recombination. The recombination activating gene-1 (RAG-1) and RAG-2 encode the essential and lymphocyte-specific components of V(D)J recombination machinery. Their products are sufficient for the recognition and initial cleavage of DNA containing recombination signal sequences that flank each coding segment. 1, 2 During lymphocyte development, expression of RAG-1 and RAG-2 is tightly regulated. RAG genes are expressed in immature B-or T-lineage cells undergoing Ig or TCR gene rearrangements. [3] [4] [5] [6] The failure of functional expression of RAG causes a defect in the formation of the functional antigen receptor of lymphocytes, and hence causes the block of lymphocyte development in mice and humans. [7] [8] [9] [10] The transcription of RAG is regulated at different levels. At the chromatin level, Fuller and Storb 11 and Kitagawa et al 12 have demonstrated that alteration of chromatin structure detected by DNase I hypersensitivity was noted in the promoter region of mouse and human RAG-1 only in RAG-expressing lymphocytes, indicating that chromatin remodeling is one of the mechanisms for regulating RAG expression. At the cis-element level, Yu et al have demonstrated that about 10 kb 5Ј upstream region of RAG-2 is necessary for the expression of RAG in B-lineage cells and in CD4 Ϫ CD8 Ϫ thymocytes, and that further upstream region is required for the expression of RAG in CD4 ϩ CD8 ϩ thymocytes. 13 Monroe et al have demonstrated that about 10 kb 5Ј upstream region of RAG-2 is enough for rescuing B-and T-cell development in RAG2 Ϫ/Ϫ mice by using RAG-2 Ϫ/Ϫ blastocyst complementation. 14 These results suggest that expression of RAG is regulated by the cis-element, such as enhancer. At the promoter level, it was reported that the human RAG-1 promoter region does not confer the lymphocyte-specific expression of RAG-1. 12, [15] [16] [17] Regarding the promoter of RAG-2, about 300 bp 5Ј upstream region from the major transcription initiation site of mouse RAG-2 is conserved between mice and humans, [17] [18] [19] indicating that this region is important for the promoter activity of RAG-2. It was also demonstrated that the human RAG-2 promoter is activated not only in lymphoid cells but also in nonlymphoid cells. 17 Concerning the mouse RAG-2 promoter, Schlissel and his colleagues and Kishi et al have demonstrated that the core promoter of mouse RAG-2 confers lymphoid specificity and may be regulated with distinct transcription factors: Pax-5 18, 19 in B cells and GATA3 18 or c-Myb 20 in T cells.
c-Myb protein is a transcription factor that is predominantly expressed in immature hematopoietic cells of all lineages and regulates cell proliferation and differentiation. 21 c-Myb antisense oligonucleotide inhibited hematopoietic colony formation 22 and mice deficient for c-Myb showed defective hematopoiesis in fetus. 23 To activate lineage-specific genes in different hematopoietic precursor cells, c-Myb functioned in a combinational manner with other transcription factors. 24 Some transcription factors, such as core-binding factor/PEBP2, 25 C/EBP␣, or PU.1, 26 have been shown to cooperate with c-Myb to activate enhancer or promoter without specifically binding to c-Myb. The other transcription factors, such as C/EBP⑀ 27 have been reported to directly bind to c-Myb and cooperatively activate the transcription. It was also reported that c-Myb interacted with coactivators, such as CBP, to activate transcription. 28 Here we extended the study on transcriptional regulation of mouse RAG-2 in B-lineage cells and demonstrated that c-Myb interacts with Pax-5 and activates the mouse RAG-2 promoter in B cells.
Materials and methods

Cells and cell culture
The 18.8.1 pre-B cell line 18 and the BAL17 B cell line, 18 both of which express endogenous murine RAG-1 and RAG-2, were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C in 5% CO 2 atmosphere. 293T, a human embryonic kidney cell line, was grown in Dulbecco modified Eagle medium containing 10% fetal calf serum, 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C and 5% CO 2 .
Plasmid constructs
Luciferase constructs used for promoter assay were prepared using PicaGene basic vector 2 (Nippon Gene, Tokyo, Japan) as described previously. 18 Luciferase constructs containing the mutation in putative c-Myb binding sites (c-Myb1 and c-Myb2 in Figure 2A ) were prepared by producing the promoter fragment by a sequential polymerase chain reaction (PCR). First, a 5Ј fragment and a 3Ј fragment containing the mutated sequence were prepared by PCR using oligonucleotide 1 (5Ј-TTCTGTCTCCCTCAACCATC-3Ј, Ϫ85/Ϫ66 of RAG-2) and either oligonucleotide 2 (5Ј-ACGGGAGTAAATCACTGTGACCT-3Ј, for c-Myb1m, Ϫ19/Ϫ41 of RAG-2) or oligonucleotide 3 (5Ј-TGCTGGTGTAAAGC-GAGTAACTGA-3Ј, for c-Myb2m, Ϫ9/Ϫ32 of RAG-2), and by PCR using either oligonucleotide 4 (5Ј-AGGTCACAGTGATTTACTCCCGT-3Ј, for c-Myb1m, Ϫ41/Ϫ19 of RAG-2) or oligonucleotide 5 (5Ј-TCAGTTACTCGCTT-TACACCAGCA-3Ј, for c-Myb2m, Ϫ32/Ϫ9 of RAG-2) and oligonucleotide 6 (5Ј-GGGGTACCATGGCCAGAGGGGCTGCTTATC-3Ј, ϩ147/ϩ118 of RAG-2), respectively. Then the full length Ϫ86/ϩ147 fragments containing mutated sequences were prepared by PCR using oligonucleotides 1 and 6 and cloned into PicaGene basic vector 2. Mouse ␤TCR 3Ј enhancer was cloned into the luciferase constructs as described previously 18 and used for transfection into B-cell lines. Luciferase constructs without enhancer were used for transfection into 293T cells. The mouse c-Myb expression vector (pAct-c-Myb) and its mutants 29 were kindly provided by Dr Ishii at Riken, Tsukuba, Japan. Pax-5 expression vector (pEFBOS-Pax-5) was generated by preparing the Pax-5 cDNA by reverse transcriptase (RT)-PCR and cloning it to the pEF-BOS vector. 30 
Luciferase reporter assay
For transfection into B-cell lines, luciferase constructs were transfected using diethylaminoethyl (DEAE) dextran method as described previously. 18 pSR␣-LacZ gene was used as an internal control. When the expression vector encoding dominant-negative mutant c-Myb (pAct-⌬TA) was cotransfected with different doses, the total amount of DNA was adjusted by adding pAct vector DNA. Twenty-four hours after transfection, cells were harvested, and luciferase activity and ␤-galactosidase activity were measured as described previously. 18 For transfection into 293T cells, the calcium/phosphate method was used as described previously. 18 Forty-eight hours after transfection, cells were harvested, and luciferase activity and ␤-galactosidase activity were measured. When c-Myb or Pax-5 expression vectors were transfected with different doses, the total amount of DNA was adjusted by adding either pAct vector DNA or pEF-BOS vector DNA.
Electrophoresis mobility shift assay
Nuclear extracts were prepared. 18 Electrophoresis mobility shift assay (EMSA) was performed by incubating nuclear extracts with radiolabeled oligonucleotides and then subjecting them to electrophoresis as described previously. 18 For supershift assay, 0.5 g polyclonal Pax-5 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or control IgG was added to the extract prior to oligonucleotide addition. Where indicated, the radioactivity of the DNA/protein complex was measured by BAS2000 (Fuji Film, Tokyo, Japan). Oligonucleotides containing the consensus binding site for c-Myb, mutated c-Myb binding site, Pax-5 binding site, mutated Pax-5 binding site, and the GATA binding site used for competition were 5Ј-TTACAGGCATAACGGTTCCGTAGTGA-3Ј, 5Ј-TACAGGCATAT-CGGTTCCGTAGTGA-3Ј, 5Ј-TACCCTTGATCAAAGCAGTGTGACGG-TAGC-3Ј, 5Ј-GACCCTTGATCAAAGCAGTATGATGGTAGC-3Ј, and 5Ј-CACTTGATAACAGAAAGTGATAACTCT-3Ј, respectively.
Precipitation of c-Myb and Pax-5 by DNA-sepharose
To prepare DNA-sepharose beads, oligonucleotides containing Ϫ41/Ϫ17 sequences of mouse RAG-2 promoter, 5Ј-ATGCATGCATGAGGTCACAGT-CAGTTACTCCCGTT -3Ј and 5Ј-ATGCATGCATAACGGGAGTAACT-GACTGTGACCTC-3Ј, were annealed and coupled to cyanogen bromideactivated sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden) as previously described. 31 As a control, oligonucleotides containing the STAT3 binding site (5Ј-TCGACTCGTTCCCAGCAGCAC-3Ј) were coupled to the beads. A quantity of 100 L nuclear extracts was added to 100 L of 1x binding buffer (4% ficoll, 20 mM HEPES, pH 7.9, 50 mM KCl, 1 mM ethylenediaminetetraacetic acid [EDTA], 1 mM dithiothreitol [DTT], 0.25 mg/mL bovine serum albumin [BSA] ) and precleared with 10 L of sepharose 4B beads at 4°C for 1 hour. Then 50 L extracts was diluted to 90 L in 1x binding buffer containing 0.13 g/L poly(dI-dC) and incubated with 10 L DNA-sepharose beads at 4°C for 3 hours. The beads were washed with 1x binding buffer 5 times. Bound proteins were eluted by boiling in sodium dodecyl sulfate (SDS)-sample buffer, resolved in SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to PolyScreen polyvinylidenefluoride (PVDF) membrane (NEN Life Science Products, Boston, MA). The membrane was incubated with c-Myb monoclonal antibody (clone 1.1; Upstate Biotechnology, Lake Placid, NY) or polyclonal Pax-5 antibody described above, followed by peroxidaseconjugated anti-mouse IgG or anti-goat IgG, and finally developed using the ECL system (Amersham Pharmacia Biotech).
Results
The ؊41/؊17 region is essential for the murine RAG-2 promoter
To determine the minimal region for activation of the murine RAG-2 promoter, the luciferase reporter gene connected to the Ϫ1.1 kb to ϩ147 region of the murine RAG-2 or its serial deletion was transfected into the 18.8.1 pre-B-cell line or the BAL17 B-cell line ( Figure 1 ). Luciferase constructs linked to Ϫ1.1 kb/ϩ147 showed the luciferase activity about 8-fold to 10-fold higher than that of the promoterless construct. Deletion of the RAG-2 promoter from Ϫ1.1 kb to Ϫ65 did not affect the promoter activity in both cell lines. Deletion to Ϫ41 reduced the promoter activity to about half, and deletion to Ϫ16 completely abolished the promoter activity, showing that the Ϫ41 to Ϫ16 region was essential for murine RAG-2 promoter activity. We and others have previously shown that the Ϫ41/Ϫ17 region of the RAG-2 promoter is highly conserved between humans and mice ( Figure 2A and see Kishi et al 18 and Lauring and Schlissel 19 ) and that Pax-5 binds the Ϫ41/Ϫ17 region. [17] [18] [19] A database search for putative binding sites of transcription factors in the murine RAG-2 promoter showed the putative c-Myb-binding elements (5Ј-AACKGNC-3Ј) at Ϫ27 (c-Myb1) and at Ϫ18 (c-Myb2). In order to examine whether c-Myb as well as Pax-5 bind the Ϫ41/Ϫ17 RAG-2 promoter, the DNA-sepharose precipitation assay was performed. Nuclear extracts prepared from 18.8.1 cells or 293T transfectant which had been transfected with mock, pAct-c-Myb, or pEFBOS-Pax-5 were incubated with the sepharose beads conjugated with the Ϫ41/Ϫ17 fragment, and the binding of c-Myb or Pax-5 to the fragment was assessed by Western blot analysis using an antibody against either c-Myb or Pax-5. As a control, sepharose beads conjugated with oligonucleotide containing STAT3 binding site were used. As shown in Figure 2B , the Ϫ41/Ϫ17 fragment precipitated c-Myb and Pax-5 from nuclear extracts of 18.8.1 cells as well as from c-Myb or Pax-5 transfectant, but not from Mock transfectants. On the contrary, the control fragment did not precipitate either c-Myb or Pax-5.
In order to verify the binding of c-Myb and Pax-5 in the nuclear extracts of B-cell lines to the Ϫ41/Ϫ17 fragment, EMSA was performed using nuclear extract prepared from 18.8.1 cells ( Figure  2C ) or BAL17 cells. A specific complex (C) was detected in the gel and the complex formation was completely inhibited by an excess of the oligonucleotide containing consensus binding site for c-Myb or Pax-5, but not by an excess of oligonucleotides containing the mutant c-Myb, the mutant Pax-5, or unrelated GATA binding sites. The addition of Pax-5 antibody shifted the majority of this complex higher in the gel, whereas control IgG had no effect, suggesting that Pax-5 is present in this complex. We could not detect a supershift of the complex using several commercially available antibodies against c-Myb, probably because these antibodies were unsuitable for the supershift assays (data not shown). Nevertheless, the results indicate that c-Myb and Pax-5 in nuclear extracts of the B-cell line concurrently bind the Ϫ41/Ϫ17 RAG-2 promoter region. The mobility of this complex was almost similar to that of the complex formed with recombinant Pax-5 or recombinant c-Myb produced in 293T cells ( Figure 2C ). This may be due to the similar electrostatic properties of the DNA/protein complexes formed with Pax-5 alone, c-Myb alone, and their combination. The similar observation was reported in glucocorticoid-responsive element (GRE) that the mobility of the complex of GRE and glucocorticoid receptor (GR) alone was the same as that of the tertiary complex of GRE/GR/STAT3. 32
c-Myb activates the RAG-2 promoter by binding to the c-Myb1 site in the promoter region
To determine which putative c-Myb elements are involved in the activation of the RAG-2 promoter in B-cell lines, luciferase construct with the wild-type Ϫ86/ϩ147 region or its mutation at the c-Myb1 or c-Myb2 site ( Figure 2A ) was transfected into 18.8.1 or BAL17 cells ( Figure 3A) . The mutation at the c-Myb1 site markedly reduced the promoter activity of the Ϫ86/ϩ147 fragment, although mutation of the c-Myb2 site did not affect its promoter activity. To verify whether c-Myb binds the c-Myb1 element at Ϫ27 of the murine RAG-2 promoter, a radiolabeled Ϫ41/Ϫ17 fragment was incubated with nuclear extracts prepared from 293T cells which had been transfected with pAct-c-Myb ( Figure 3B ). The complex formation (C1) was noted in the gel, which was inhibited by an excess of unlabeled wild-type oligonucleotides, but not mutant oligonucleotides for c-Myb1. This result indicates that c-Myb binds the c-Myb1 site in the Ϫ41/Ϫ17 region. Recombinant Pax-5 also bound the Ϫ41/Ϫ17 fragment and formed the complex (C2), which was inhibited by the unlabeled probe oligonucleotide ( Figure 3B ). This complex formation was inhibited by oligonucleotide containing consensus Pax-5 binding site, but not by oligonucleotide containing mutated Pax-5 binding site as previously reported. 18 Importantly, the binding of recombinant Pax-5 was completely inhibited by an excess of unlabeled Ϫ41/ Ϫ17 oligonucleotide containing mutant c-Myb1 site ( Figure 3B ), indicating that mutation of c-Myb1 site did not affect the binding of Pax-5 to the mouse RAG-2 promoter.
c-Myb and Pax-5 cooperatively activate the RAG-2 promoter
To examine the effect of c-Myb and Pax-5 on the activation of the RAG-2 promoter, 293T cells were transfected with luciferase construct with Ϫ86/ϩ147 RAG-2 promoter or its mutants alone, or together with either pAct-c-Myb or pEFBOS-Pax-5, or both, and luciferase activity was determined (Figure 4) . Each Pax-5 or c-Myb maximally activated the RAG-2 promoter about 3-fold when compared with the promoter activity without Pax-5 and c-Myb, and their combination maximally activated the promoter about 9-fold ( Figure 4A ). This cooperation between c-Myb and Pax-5 was found by the wild-type promoter (WT) and c-Myb2 site-mutant promoter (c-Myb2m). However, the cooperation was significantly reduced when the c-Myb1 site-mutant promoter (c-Myb1m) was used ( Figure 4B ). These results show that c-Myb and Pax-5 cooperatively activate the RAG-2 promoter and that the c-Myb1 site in the promoter is important for the cooperation. To test the possibility that c-Myb and Pax-5 synergistically bind the RAG-2 promoter, a radiolabeled Ϫ41/Ϫ17 fragment was incubated Figure 3C .
To determine the functional domain in c-Myb necessary for the interaction with Pax-5, a radiolabeled Ϫ41/Ϫ17 fragment was incubated with nuclear extracts prepared from 293T cells transfected with expression vectors for wild-type c-Myb or its deletion mutants in the absence or presence of that of Pax-5 ( Figure 5B) . Deletion of the C-terminus of c-Myb (CT1) abolished the cooperation of c-Myb and Pax-5 for DNA binding ( Figure 5B , middle panel), although the amount of CT1 in the nuclear extract was comparable to that in the other mutants or wild type ( Figure 5B 
Dominant-negative c-Myb suppresses RAG-2 promoter activity
In order to examine the role of c-Myb in the activation of the RAG-2 promoter in vivo, 293T cells were transfected with luciferase construct with Ϫ86/ϩ147 RAG-2 promoter alone, or together with pEFBOS-Pax-5 plus pAct-c-Myb and various amounts of pAct-⌬TA, which encodes transactivation domain-deleted c-Myb mutant (⌬TA) ( Figure 5B ). After transfection, luciferase activity was determined. As shown in Figure 6A , ⌬TA suppressed c-Myband Pax-5-dependent RAG-2 promoter activation in a dosedependent manner. To verify the role of c-Myb in the activation of the RAG-2 promoter in B cells, 18.8.1 cells were transfected with luciferase construct with Ϫ86/ϩ147 RAG-2 promoter alone, or together with pAct-c-Myb and various amounts of pAct-⌬TA, and the luciferase activity was assessed. ⌬TA dose-dependently suppressed the RAG-2 promoter activation in the B-cell line ( Figure  6B ). The result indicates the involvement of endogenous c-Myb in the activation of the RAG-2 promoter in a B-cell line.
Discussion
We and others have shown that the mouse RAG-2 promoter region confers lymphocyte-specificity. 18, 19 In B-lineage cells, it was demonstrated that Pax-5 plays an important role for activation of mouse RAG-2 promoter. 18, 19 In T-lineage cells, we indicated the role of GATA-3 in the activation of the promoter, 18 The sequences of the Ϫ41 to Ϫ16 region of mouse RAG-2 and that of human RAG-2 are almost identical and confer core promoter activity in B-cell lines (Figure 1 and Figure 2A Figure 2C . To verify specific binding, 50-fold excess of unlabeled Ϫ41/Ϫ17 oligonucleotide (WT), or 50-fold or 200-fold excess of a similar oligonucleotide containing mutations at the c-Myb1 site (c-Myb1m) was included in EMSA. Specific DNA/protein complex is indicated as C1 (for c-Myb) and C2 (for Pax-5), and free probe as F. Two bands are detected for c-myb (C1), probably reflecting the monomer (lower band) and dimer (upper band) formation of c-Myb protein(s) in the gel Pax-5. 29 the promoter activity became about half when the Ϫ65/Ϫ42 region was deleted (Figure 1) . The Ϫ65/Ϫ42 region was not conserved between mice and humans as previously shown. 18, 19 When we compared this region between mice and humans in more detail, guanine in Ϫ53 to Ϫ42 in the mouse RAG2 promoter region was substituted to adenine in the human RAG2 promoter (Figure 2A and Kishi et al 18 and Lauring and Schlissel 19 ). This indicates that some transcription factor(s) might bind this site, although it is only speculation.
It was demonstrated that c-Myb was expressed in the cortex of thymus, comprised of immature T-cells, but not in the medulla. 33 Expression of the dominant-negative c-Myb mutant in the Tlineage in mice partially blocked T-cell differentiation in thymus, 34 and in homozygous null c-Myb/RAG1 chimeric mice, T-cell development was blocked at the CD4 Ϫ CD8 Ϫ stage. 35 The results indicate the inevitable role of c-Myb in T-cell development. In accordance with these results, Wang et al indicated that c-Myb is essential for RAG-2 promoter activity in T-lineage cells. 20 Recently, Akashi et al have reported that c-Myb is not expressed in freshly isolated pro-B or pre-B populations. 37 However, Allen et al have shown that in homozygous null c-Myb/RAG1 chimeric mice, B-cell development is blocked at the pre-B-cell stage in the bone marrow. 35 The result verifies an important role of c-Myb in early B-cell development and is consistent with our present results.
Regarding the expression of Pax-5, it initiated from the early B-lineage precursor cells and persisted to mature B-cells. It was down-regulated in terminally differentiated plasma cells. 38, 39 In Pax-5 mutant mice, B-cell development was completely arrested at the pro-B stage. 40 Precursor cells in the bone marrow of Pax-5 mutant mice could give rise to pre-B cells, in which the D H -to-J H rearrangement occurred at normal frequency, but the frequency of the V H -to-DJ H rearrangement reduced about 50-fold, 41 showing that Pax-5 is dispensable for D H -to-J H recombination. Concerning the role of Pax-5 for RAG expression, Lauring and Schlissel 19 and Kishi et al 18 have demonstrated that Pax-5 plays an important role for activation of mouse RAG-2 promoter in B-lineage cells. In this study, we have demonstrated that not only Pax-5 but also c-Myb is involved in the promoter activation in B-cell lines. It is conceivable that the activation of the mouse RAG-2 promoter is regulated with cooperation of multiple transcription factors including c-Myb and Pax-5. It is worthy to note that in the 5Ј upstream region of the mouse and human RAG-2 promoter, up to 300 bp from the major transcription initiation site are conserved. [17] [18] [19] These promoter sequences must have been conserved because of their inevitable roles in RAG-2 expression, although the in vitro luciferase system so far failed to demonstrate its essential roles (Figure 1 ). With this regard, some regulatory regions such as the local control region (LCR) 42 may exist which control chromatin remodeling as well as transcriptional activity in vivo, but show very low transactivation activity in vitro as employed in this study.
In the present study, we showed that c-Myb and Pax-5 cooperatively bind to synergistically activate the mouse RAG-2 core promoter in B-cell lines (Figure 2-Figure 5 ). Concerning the interaction of c-Myb and Pax-5, we observed the synergistic activation, albeit reduced, of the RAG-2 promoter with the mutated c-Myb binding site (c-Myb1 site) by recombinant Pax-5 and c-Myb ( Figure 4B ). We also found that the c-Myb mutant without its DNA-binding domain (NT4 and ⌬DB) could augment the binding of Pax-5 to the promoter ( Figure 5B ). Finally, we demonstrated that c-Myb and Pax-5 were coprecipitated by an antibody to c-Myb in the absence of target DNA ( Figure 5C ). These observations strongly suggest the direct protein-protein interaction between c-Myb and Pax-5. With respect to the interaction of Pax-5 and c-Myb, we demonstrated that interaction between c-Myb and Pax-5 required the C-terminal region of c-Myb ( Figure 5B ). Although the DNA-binding domain and transactivation domain of c-Myb have been reported to be necessary for the interaction of c-Myb with other transcription factors, 24 the role of the C-terminal region has not been described. Thus, this study demonstrates for the first time the functional role of the C-terminal of c-Myb.
Regarding the transcriptional role of c-Myb functional domains ( Figure 5) , 24, 29 it has been demonstrated that the transactivation domain of c-Myb directly or by binding to a coactivator, such as CBP or p300, 24 activates transcription. In the present study, we showed that the c-Myb mutant of the transactivation domain (⌬TA) suppressed RAG-2 promoter activation in B-cell lines ( Figure 6 ). The result indicates that ⌬TA functioned as a dominant-negative c-Myb mutant and implies that the transactivation domain of c-Myb may play a role in activation of the RAG-2 promoter in B cells. Alternative interpretation of the result would be that ⌬TA bound the promoter and inhibited the binding of Pax-5 to the promoter. This is unlikely, because the ⌬TA mutant did not block but rather augmented the binding of Pax-5 to the promoter ( Figure  5B ). The DNA-binding domain of c-Myb also plays a role in the promoter activation, because mutation of c-Myb binding sites in the promoter reduced the promoter activity in B cells ( Figure 3A) . However, as shown in Figure 5B , the c-Myb deletion mutant of the DNA-binding domain, NT4, could also bind the promoter by cooperating with Pax-5, indicating that the DNA-binding domain may play a role other than DNA-binding in RAG-2 promoter activation. In this context, it is noteworthy that NT4 inhibited the RAG-2 promoter activation in B cells (data not shown). The DNA-binding domain of c-Myb not only binds DNA but also interacts with other transcription factors or coactivators, such as C/EBP␤ or p100. 24 Thus, the DNA-binding domain of c-Myb may play a role not only in DNA-binding but also in interacting with other transcription factors to activate the RAG-2 promoter. Taken together, the hematopoietic but not lineage-specific transcription factor, c-Myb, cooperates with the B-cell-specific transcription factor, Pax-5, 38, 39 and activates the RAG-2 transcription in Blineage cells. Further study is necessary to clarify whether other transcription factors are involved in RAG-2 promoter activation in B-lineage cells.
